Last reviewed · How we verify
Carvedilol 6.25 mg
Carvedilol 6.25 mg, marketed by Kafrelsheikh University, is a well-established drug in the cardiovascular segment. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk lies in potential generic competition post-patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Carvedilol 6.25 mg |
|---|---|
| Also known as | Carvipress 6.25 mg |
| Sponsor | Kafrelsheikh University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Carvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis. (NA)
- HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy (PHASE2)
- Clinical Application of Simcyp-Guided Doses of Antihypertensive Drugs in Cirrhotic Patients (PHASE4)
- Carvedilol vs. Propranolol for Preventing Rebleeding After Endoscopic Treatment of Cirrhotic Varices (PHASE4)
- CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes (PHASE3)
- CARPEUS : Effect of Carvedilol on the Portosystemic Gradient as Measured by Endoscopic Ultrasound (NA)
- Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis (NA)
- Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carvedilol 6.25 mg CI brief — competitive landscape report
- Carvedilol 6.25 mg updates RSS · CI watch RSS
- Kafrelsheikh University portfolio CI